No Data
No Data
Protagonist Therapeutics Is Maintained at Market Outperform by JMP Securities
Protagonist Therapeutics Price Target Cut to $43.00/Share From $45.00 by JMP Securities
Express News | HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $40
Protagonist Therapeutics Analyst Ratings
Express News | Protagonist Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $40 From $38
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $43
No Data